Opinion: New Medicare policies will keep important pain relief from some patients

Peripheral nerve blocks place numbing medicine around a nerve. They interrupt pain signals, making them useful both as a diagnostic test and as treatment. This matters because chronic pain can dominate daily life, while a temporary block may sometimes bring relief that lasts longer than the medicine’s few-hour effect.

In the article, a targeted block made a patient’s chronic pelvic pain disappear. The mechanism is direct: numbing the suspected nerve shows whether it is carrying the painful signal. It can also create a window in which a patient sleeps, moves, or participates in other care with less suffering.

Blocks are not presented as stand-alone cures. They fit multimodal, multidisciplinary treatment and may help reduce medications, support physical therapy, and avoid emergency visits or more invasive care. Coverage changes could limit access, while better studies may clarify which patients benefit.

Beginning in late October, five regional Medicare Administrative Contractors are applying new policies that restrict coverage for many peripheral nerve procedures. These procedures are used to diagnose and treat chronic pain. The final policy is less restrictive than the proposal released in 2025, but it still narrows access for patients with severe, high-impact pain.

The policy excludes therapeutic procedures targeting nerves such as the pudendal nerve and ganglion impar. These interventions are used for some forms of severe pelvic pain. The article describes patients who received relief after pain made sitting, dressing, having sex, or completing ordinary daily activities excruciating.

The changes reflect contractors’ concerns about limited evidence for some treatments. However, they may also reduce access to non-opioid care used alongside physical therapy and other treatments. The physician argues that coverage should preserve appropriate access while stronger evidence is collected.

The new policies are issued by five regional Medicare Administrative Contractors. Together, these contractors determine local oversight across 37 states and several U.S. territories. Their decisions therefore reach far beyond one clinic or one kind of pain, affecting how many providers’ Medicare claims are handled.

The article says the restrictions could affect millions of patients with severe pain. It does not provide a more precise number of patients or specify exactly how many territories are included. That distinction matters: the geographic scope is stated clearly, while the patient figure remains broad.

Patients with pelvic pain and other chronic conditions could lose coverage for procedures used for diagnosis or treatment. The effects may include fewer options within non-opioid, multidisciplinary care. The article calls for better research while preserving access to treatments that meaningfully help some patients.

If Medicare stops covering these nerve procedures, patients with severe chronic pain may lose an important non-opioid treatment option. The article warns that people could lose access to care that helps them sleep, buy groceries, leave home, or spend part of the day without overwhelming pain.

The clearest examples involve severe pelvic pain. Procedures targeting the pudendal nerve or ganglion impar have helped patients who found sitting, dressing, sex, or ordinary daily life excruciating. A targeted block can interrupt pain signals and create relief that supports basic function.

The consequences may extend beyond pain itself. Peripheral nerve interventions can help patients participate in physical therapy, reduce medications, avoid emergency visits and hospitalizations, and delay or avoid surgery. Losing coverage could narrow individualized care, especially for patients who have already been passed between doctors without effective help.

Medicare Administrative Contractors, or MACs, are private companies that handle much of Medicare’s operational machinery. The Centers for Medicare and Medicaid Services writes and oversees Medicare rules, but MACs apply those rules locally. This division matters because regional contractors influence whether particular procedures are covered for individual patients.

The article describes five MACs issuing policies that determine local oversight across 37 states and several U.S. territories. When providers submit claims, these contractors help evaluate them under Medicare’s rules. Their policies can therefore shape access to procedures used to diagnose or treat chronic pain.

MACs are not described as writing the national Medicare program. Instead, they administer and interpret coverage requirements for local claims. Their stated concern is evidence quality for certain procedures. Their decisions now restrict some peripheral nerve treatments, while patients and physicians argue for continued access during further research.

Medicare contractors consider evidence insufficient for some nerve procedures because existing research has important limits. They point to small studies, short follow-up periods, and uncertainty about whether benefits last. Their concern is whether the available evidence is strong enough to support coverage for several procedures.

The article does not dismiss those concerns. It acknowledges that some procedures may be used too often, may not work for everyone, or could be influenced by financial incentives. Not every nerve block helps, and Medicare should not pay indefinitely for treatments that provide no benefit.

The proposed path forward is better evidence rather than simply abandoning access. The article calls for larger studies, longer-term follow-up with patients, and federal funding for research. It also supports gathering real-world evidence while preserving appropriate access to effective non-opioid treatments for patients who benefit.

Chronic pain is difficult to study because pain is subjective and each patient experiences it differently. A treatment may show limited average benefit across a study population while producing profound relief for one person. Population-level evidence remains important, but it cannot always identify which patients will experience a meaningful improvement.

The article’s examples show why this matters. A nerve block eliminated one patient’s severe pelvic pain and helped others regain basic activities. The block interrupts signals around a targeted nerve, while the broader treatment plan can address function, movement, and medication needs.

Multimodal, multidisciplinary care responds to this variability. Peripheral nerve interventions can help patients participate in physical therapy, decrease medications, avoid emergency visits and hospitalizations, or delay surgery. The article calls for stronger research while keeping appropriate access to individualized non-opioid treatment.